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on these ﬁndings, a framework consisting of key characteristics of an AED scheme 
was developed and, subsequently, applied to an inventory of existing AED schemes, 
compiled through a comprehensive review of relevant peer-reviewed and ‘grey’ litera-
ture available as of August 2009. RESULTS: The framework contained 11 character-
istics of AED schemes grouped into 3, sequential categories: 1) System level (Decision 
problem; Objective; Engagement; Evaluation); 2) Organisational (Governance; 
Financing); and 3) Research design (Scope; Level of Operation; Test Criterion; Test 
Implementation; Response to Test Result). It was applied to the inventory in the form 
of a checklist, similar to other critical appraisal tools. In general, information found 
for each of the schemes was limited and did not address questions comprising the 
checklist. CONCLUSIONS: Information upon which to evaluate AED schemes is 
sparse, yet necessary for moving forward with efforts to ensure their use represents 
value for money.
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OBJECTIVES: This study examines the availability of and eligibility requirements for 
pharmaceutical patient assistance programs (PAPs) for the most commonly prescribed 
medications in the United States. METHODS: RxAssist.org, an electronic database of 
PAPs, was utilized to collect information on the availability (brand and/or generic) 
and eligibility (citizenship, permanent residency, insurance, and income limits) for each 
of the “Top 200 drugs by dispensed prescriptions” for 2008. Pharmaceutical compa-
nies were contacted directly or their websites were searched when additional clariﬁca-
tions were needed. Chi-square analyses were used to assess for differences in eligibility 
requirements by drug availability (brand or generic). RESULTS: Of 136 unique chemi-
cal entities, 111 (81.6%) of these drugs were available in RxAsisst.org. 69 (62.2%) 
of the available drugs were brand only, 29 (26.1%) generic only and 13 (11.7%) had 
both brand/generic forms. There were differences found in PAP eligibility requirements 
for citizenship (p < 0.001), permanent residency (p < 0.001), and private insurance 
status (p < 0.001) by drug availability (brand versus generic), but not for income limits 
(p = 0.051). Some programs allow Medicare Part D patients to apply for PAP; 
however, each claim is evaluated on case-to-case basis. CONCLUSIONS: Both brand 
and generic drugs are widely available to low-income applications through PAPs, but 
results suggest that U.S. citizenship and permanent residency are more likely to be 
required by PAPs for brand versus generic drugs. PAPs also provide some options for 
the underinsured—those with either private insurance or Medicare Part D coverage.
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OBJECTIVES: To evaluate whether socioeconomic status (SES) plays a role in the 
patient’s decision to accept (purchase) continuous positive airway pressure (CPAP) 
treatment for obstructive sleep apnea syndrome (OSAS) (according to the Israeli 
National Health Insurance Law, purchasing CPAP treatment requires an out-of-pocket 
payment). METHODS: Cross-sectional prospective study in the University-afﬁliated 
Sleep Disorder Center in Beer-Sheva, Israel. Adult patients (age > 18 years), suspected 
of having OSAS, were consecutively recruited between March 2007 and December 
2007. Questionnaires were completed prior to diagnosis to elicit socioeconomic status, 
sleeping habits, and access to sources of information on OSAS and its treatments. At 
the conclusion of the adaptation period, a second questionnaire was completed to 
explore the reasons for commencing or declining treatment. RESULTS: Among the 
newly diagnosed (polysomnographically) adult OSAS patients, 162 required CPAP 
and underwent attendant titration and a 2-week adaptation period. Only 40% of these 
patients (n = 65) decided to purchase CPAP therapy. They were older, and typically 
they had higher apneahypopnea indexes (AHIs) and higher income levels than the 
patients who declined CPAP treatment. Multivariate logistic regression (adjusting for 
body mass index and Epworth Sleepiness Scale) revealed that whether a patient pur-
chased CPAP was determined by (OR, 95% CI): income level (2.4; 1.2–4.6), age (+1 
year) (1.07; 1.01–1.1), AHI (≥ 35 vs. < 35 events/hr) (4.2, 1.4–12.0), receiving positive 
feedback about the experiences of family or friends with CPAP (2.9, 1.1–7.5), and 
sleeping separate from spouse (4.3, 1.4–13.3). CONCLUSIONS: In addition to the 
already known determinants of CPAP acceptance, patients with low SES were less 
receptive to CPAP treatment than those with higher SES. CPAP support and patient 
education programs should be tailored for low SES people in order to increase rates 
of treatment initiation and adherence.
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OBJECTIVES: There is a lack of understanding and empirical basis regarding what 
factors are important in the Medicare National Coverage Determination (NCD) deci-
sion making process. The objective of this study was to determine what factors predict 
favorable coverage decisions. METHODS: NCDs from 1999 through 2007 were 
reviewed using publicly available decision memoranda posted on the CMS website (n 
= 140). Data abstracted from decision memoranda were supplemented with cost-
effectiveness information identiﬁed from an independent literature review. When a 
decision memo included coverage decisions for multiple technologies or indications, 
an entry was made for each coverage decision in the memorandum. The United States 
Preventative Services Task Force (USPSTF) guidelines were used to grade the support-
ing clinical evidence. We created a dataset with the following variables: quality of 
supporting clinical evidence; availability of alternative interventions; cost-effectiveness 
of intervention; intervention type, and coverage requestor. Logistic regression was 
used to determine what variables predicted favorable coverage. RESULTS: Good 
quality supporting clinical evidence was associated with an odds ratio (OR) of favor-
able coverage (95% CI) of 12.74 (3.02–53.74). Interventions estimated to be domi-
nant, i.e. less costly and more effective, or have an estimate of cost-effectiveness of < 
$50k per QALY were associated with an OR of 18.86 (4.62–77.00) and 3.91 (1.00–
15.40) respectively. Availability of alternative interventions for the same indication 
was associated with a decreased likelihood of coverage with an OR of 0.01 (0.03–
0.33). Type of intervention, and coverage requestor were not signiﬁcant predictors. 
CONCLUSIONS: The ﬁndings suggest that good quality supporting clinical evidence 
and favorable estimates of cost-effectiveness predict favorable CMS coverage deci-
sions. The availability of alternative interventions for the same indication reduced the 
likelihood of a favorable coverage decision. The ﬁndings indicate that Medicare’s 
coverage process is evidence and value-based, though more research is needed on the 
impact of decisions.
PHP18
EVALUATION OF MEDICARE PART D PHARMACY AND MEDICAL 
UTILIZATION PATTERNS BY COVERAGE PHASE FOR COMMON 
CHRONIC DISEASES
Priest J1, Sklar A2, Engel-Nitz N2, Shenolikar R1, Cantrell C1
1GlaxoSmithKline, RTP, NC, USA, 2i3 Innovus, Eden Prairie, MN, USA
OBJECTIVES: To evaluate the percent of patients reaching the coverage gap and 
catastrophic phase and their pharmacy and medical utilization for the treatment of 
common conditions (asthma, COPD, coronary artery disease, depression, diabetes, 
hyperlipidemia, hypertension (HTN), heart failure (HF)) among patients enrolled in 
Medicare Advantage with Part D coverage (MAPD). METHODS: Retrospective 
claims analysis using medical/pharmacy claims and enrollment data from a large 
National US Plan offering MAPD beneﬁts. Patients with full-year enrollment in 2007 
and ≥1 select condition based on claims in 2006 were identiﬁed. Phase transitions 
were based on pharmacy expenditures and low income subsidy and dually eligible 
patients were excluded. Outcomes included the proportion of patients ﬁlling any 
medication per national guidelines, proportion of days covered (PDC) for patients 
ﬁlling ≥1, compliance (MPR) for patients ﬁlling ≥2 and medical utilization/costs overall 
and by phase. RESULTS: The percentage of patients reaching the coverage gap ranged 
by condition from 18%–36% with 2%–6% reaching catastrophic. For all conditions, 
pharmacy utilization was lower in the coverage gap however, patients ﬁlling medica-
tions in the gap spent on average 8%(HTN) to 160%(depression) more out-of-pocket 
compared to their coinsurance phase. As with pharmacy utilization, medical also 
decreased during the coverage gap. Overall, the proportion of patients ﬁlling any 
acceptable medication for their condition ranged from 40%(COPD) to 95%(HF). The 
proportion of those with ≥80% PDC ranged from asthma(19%) to HF(76%) while 
compliance rates for patients reﬁlling (MPR ≥ 80%) ranged from Asthma(37%) to 
HF(87%). CONCLUSIONS: A fairly high percent of patients reached the coverage 
gap in 2007 and incurred substantially larger out-of-pocket expenses. Once in the gap, 
both medical and pharmacy utilization on average decreased. Medication compliance/
persistence was less than optimal overall and with up to one-third of patients reaching 
the gap there is further potential for reduced quality care that could negatively impact 
the health of an aging population.
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OBJECTIVES: This study examined the prevalence of antidepressant drug use and 
factors associated with their use among elderly nursing home residents in the Unites 
States using the 2004 National Nursing Home Survey (NNHS) data. METHODS: The 
study involved analysis of prescription and resident ﬁles of a nationally representative 
sample of residents aged ≥65 years from the 2004 NNHS data. The analysis focused 
on the prescribing of any antidepressant, including selective serotonin reuptake inhibi-
tors (SSRI), tricyclic antidepressants (TCAs), serotonin modulators, serotonin-norepi-
nephrine reuptake inhibitor (SNRI), MAO (Monoamine oxidase) inhibitors and 
‘other’ antidepressants such as mirtazapine and bupropion. A descriptive weighted 
analysis was performed to examine the prevalence patterns. Multiple logistic regres-
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sion within conceptual framework of Andersen’s Behavioral Model was used to 
examine the predisposing, enabling and need characteristics associated with antide-
pressant use. RESULTS: The overall prevalence of antidepressant use was found to 
be 46.22% (95%CI, 45.16–47.27). The most prescribed class of antidepressants was 
SSRIs (67.29%), followed by serotonin modulators (10.05%), SNRIs (6.02%), TCAs 
(5.06%) and MAO inhibitors (0.02%). Citalopram (28%) was the highest prescribed 
individual antidepressant followed by mirtazapine (22.05%). Among the predisposing 
characteristics, age, race, and marital status were signiﬁcantly associated with antide-
pressant drug use. Enabling factors like Medicare or Medicaid payment source and 
facility bed capacity predicted antidepressant use. Among need characteristics, likeli-
hood of receiving antidepressant prescription decreased with increased dependence in 
decision making ability and out of bed mobility. Also presence of depressed mood 
indicators, history of falls and fractures, and an increase in number of medications 
prescribed had positive association with antidepressant prescription. CONCLU-
SIONS: Nearly half of elderly nursing home residents received antidepressants. Pre-
disposing, need, and enabling factors played important roles in use of antidepressants. 
Overall, the study ﬁndings suggest that antidepressant treatment is highly prevalent 
in nursing homes possibly due to increased recognition of symptoms in the elderly 
population.
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OBJECTIVES: Psychotropic use in nursing homes has been a concern due to extensive 
misuse of these agents in the elderly. Very little is known about recent national level 
utilization in nursing homes especially after the introduction of newer psychotropic 
agents. Therefore, this study examined psychotropic drug use patterns among elderly 
nursing home residents at the national level by using the 2004 National Nursing Home 
Survey (NNHS) data. METHODS: This study involved retrospective, cross-sectional 
analysis of the 2004 NNHS. The study sample included patients aged 65 years or 
older. Psychotropic drugs were classiﬁed as antidepressants, sedative/hypnotics, anti-
anxiety, antipsychotics, and stimulants based on existing literature. Psychotropic 
polypharmacy was deﬁned as concomitant use of two or more psychotropic drugs. 
SAS survey procedures were used for descriptive domain analysis and to calculate 95% 
Conﬁdence Intervals (CI) of weighted estimates. RESULTS: According to the 2004 
NNHS, an estimated 0.83 (95% CI, 0.82–0.85) million elderly nursing home residents 
received at least one psychotropic medication for an overall prevalence of 63.18% 
(95% CI, 62.16—64.21), while 25.85% (95% CI: 24.92%–26.77%) received two or 
more psychotropic medications. Antidepressant agents (46.22%, 95% CI: 45.16%–
47.27%) were the most prescribed psychotropic drug class followed by antipsychotics 
agents (24.84%, 95% CI: 23.92%–25.76%). Psychotropic polypharmacy within the 
antidepressant class was highest (5.92%, 95% CI: 5.43%–6.41%) followed by anti-
psychotics (1.17%, 95% CI: 0.94%–1.39%). CONCLUSIONS: Nearly two-third 
elderly nursing home residents received psychotropic medications, while more than 
one in four residents were receiving two or more psychotropic drugs. With increasing 
concerns of inappropriate psychotropic drug use, there is a strong need to monitor 
their usage in this vulnerable population.
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OBJECTIVES: To examine the inﬂuence of inexpensive generic programs on prescrip-
tion medication acquisition behavior of patients. METHODS: Cross-sectional survey 
of 200 consecutive patients during regularly scheduled appointments to an adult 
general medicine clinic. Questions were asked to determine the type of pharmacy 
patients obtained their current prescription medication from; whether they were aware 
of focused programs selling generic medication for a reduced cost; whether they had 
ﬁlled a prescription recently using a reduced cost generic program, and if they did, 
whether they had other medications ﬁlled at the same pharmacy. Demographic data 
was also obtained. Data were analyzed using descriptive statistics. Respondents were 
categorized as having ﬁlled a prescription using an inexpensive generic program or 
not. Differences in demographics and medication-related variables between the two 
groups were analyzed using Student’s t-test for continuous variables or Chi-squared 
test for categorical variables. P value of less than 0.05 were considered statistically 
signiﬁcant. RESULTS: Only 5% of respondents (11 of 210) used an inexpensive 
generic program to ﬁll at least one of their prescriptions. Characteristics of patients 
who tended to use the generic programs included greater number of prescriptions, 
lower household income, no prescription insurance, and be of female gender. The 
study is limited in generalizability due to the small number of respondents in the group 
who had a prescription ﬁlled by an inexpensive generic program. CONCLUSIONS: 
This small study provides encouraging data to support the development of a larger 
study of the inﬂuence of the generic programs on patient behavior in regards to deci-
sion of where to obtain prescriptions. Larger studies may also attempt to determine 
whether these programs improve access to medications that patients may have had 
trouble affording before their inception.
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OBJECTIVES: Duloxetine is approved for the treatment of major depressive disorder 
(MDD) and general anxiety disorder (GAD), and for the management of diabetic 
peripheral neuropathic pain (DPNP) and ﬁbromyalgia. It has also demonstrated sig-
niﬁcant pain relief among patients with chronic lower back pain (CLBP) and osteo-
arthritis. For patients with each of these conditions, this study assessed pain medication 
use prior to duloxetine initiation. METHODS: A large, US administrative claims 
database was used to identify commercially-insured duloxetine initiators during 2007 
and 2008 who had any of the 6 medical conditions mentioned above during the 12 
months prior to duloxetine initiation. Initiation was deﬁned as no duloxetine pill 
coverage in the previous 90 days. Utilization of pain-related medications including 
antidepressants, anticonvulsants, opioids, non-steroidal anti-inﬂammatory drugs 
(NSAIDs), and muscle relaxants, was assessed over the 6 or 12 months prior to 
duloxetine initiation, respectively. RESULTS: The study identiﬁed 44,838 duloxetine 
initiators in 2008, with 13,809, 3,289, 1,501, 8,731, 7,871, and 18,987 in the MDD, 
GAD, DPNP, ﬁbromyalgia, osteoarthritis, and CLBP groups, respectively. Antidepres-
sant use was high across all conditions over the 12 months prior to duloxetine initia-
tion, especially among patients with MDD (83.5%) or GAD (78.8%). Anticonvulsant 
utilization was highest in DPNP (63.4%) and ﬁbromyalgia (55.0%), lowest in GAD 
(39.3%), but similar between other groups (ranged 42.3–48.9%). Opioid use varied 
greatly across groups (55.1–82.8%), with the highest (lowest) use among CLBP (GAD) 
patients. GAD patients had the lowest NSAID use (32.1%), while osteoarthritis 
patients had the highest utilization (59.4%). The use of muscle relaxants ranged 
between 28.2% (GAD and DPNP) and 54.5% (CLBP). Pain medication use in the 
prior 6 months showed similar patterns, but was in general about 10–15 percentage 
points lower. Results for 2007 initiators were similar. CONCLUSIONS: Patients used 
several types of pain medications prior to initiating duloxetine across disease states.
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OBJECTIVES: Over 700 new molecular entities (NMEs) were approved between 1980 
and 2008 in the U.S. Although a small percentage of these products will inevitably be 
discontinued, concerns over safety are purported to be the main impetus for discon-
tinuing a drug from the market. In this study, a trend analysis was performed to 
examine the pattern of discontinued NMEs approved by the FDA from 1980 to 2008. 
METHODS: Data were derived from the FDA, Federal Register, Micromedex, 
Medline, Lexis-Nexis, journal articles, governmental web pages and other publicly 
available documents. A drug was considered discontinued if it was deleted from the 
2009 version of the FDA’s Orange book: Approved Drug Products with Therapeutic 
Equivalence Evaluations. Descriptive statistics, chi-square tests, logistic regression, and 
survival analysis were performed. For the Kaplan-Meier survival curves, drug that 
were not discontinued during the study time-period were censored. RESULTS: A total 
of 703 NMEs were approved during the study period. Of the 101 NMEs that were 
discontinued, 29 were due to safety concerns. Controlling for other factors, the odds 
(OR:2.53; 95% CI:1.42–4.55) of a drug being discontinued for reasons other than 
safety and efﬁcacy were signiﬁcantly higher than the odds of being discontinued for 
safety reasons (p < 0.05). Compared to other therapeutic classes, anti-infective drugs 
were more likely to be discontinued (p < 0.05). Results from the Kaplan-Meier survival 
analysis revealed the estimated probability of discontinuing a NME from the market 
over a 20 year time period was 15.0%. CONCLUSIONS: Survival analysis provided 
useful estimates for the probability of discontinuation. Safety concerns for NMEs were 
not the foremost reasons for drug discontinuation; rather ﬁnancial reasons may con-
tribute to a larger portion of discontinuations. However, additional studies are needed 
to assess how probabilities for drug discontinuation are inﬂuenced by decision-making 
entities regarding drug approval, drug development and innovation, and drug policy.
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OBJECTIVES: With US health care reform proposing to extend Medicare coverage 
to individuals between the ages of 55–64, the pressure for coverage will dramatically 
increase. We examined demand ﬁve drug markets—cholesterol, diabetes, depression, 
hypertension and pain—for this age group compared to others. We also compared the 
cost burden under Medicare Part D compared payers to highlight the demand for 
more affordable drugs from individuals that are not yet eligible for Medicare coverage. 
METHODS: For each drug market, total prescriptions (TRx), new patient prescrip-
tions (NPRx), and average prescription size were obtained for each of the age groups 
analyzed (≤18, 19–35, 36–54, 55–64, ≥65). For each drug market, average out of 
pocket cost (OPC) was also compared between Medicare beneﬁciaries and other 
patients. Data were collected for eight quarters, spanning November 2007 to Novem-
